Article
The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
Endocrine-related cancer - 1 Mar 2006
Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas M A, Nistal M, Santisteban P
Abstract excerpt
The oncogene BRAF(V600E) is the most frequent genetic event in papillary thyroid carcinoma (PTC) but its prognostic impact still remains to be elucidated. We evaluated a representative series of 67 individuals with PTC who underwent total thyroidectomy. BRAF-positive tumours correlated with early recurrences (32% vs 7.6%; P=0.02) during a median postoperative follow-up period of 3 years. Interestingly, within the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.